A61K 2039/6068
Other bacterial proteins
Official title: {Other bacterial proteins, e.g. OMP}
A61K2039/6068 (Other bacterial proteins) appears on 368 US grants and 579 published applications in this corpus.
Search patents in A61K- Granted patents
- 368
- Published applications
- 579
- Assignees
- 281
- Inventors
- 1,072
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 2 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 12 | 0 |
| 1999 | 12 | 0 |
| 2000 | 6 | 0 |
| 2001 | 7 | 0 |
| 2002 | 5 | 16 |
| 2003 | 8 | 21 |
| 2004 | 9 | 17 |
| 2005 | 3 | 20 |
| 2006 | 4 | 14 |
| 2007 | 6 | 22 |
| 2008 | 2 | 19 |
| 2009 | 6 | 21 |
| 2010 | 10 | 27 |
| 2011 | 6 | 24 |
| 2012 | 9 | 15 |
| 2013 | 14 | 27 |
| 2014 | 16 | 23 |
| 2015 | 31 | 40 |
| 2016 | 16 | 31 |
| 2017 | 24 | 19 |
| 2018 | 21 | 29 |
| 2019 | 13 | 21 |
| 2020 | 20 | 26 |
| 2021 | 16 | 27 |
| 2022 | 14 | 28 |
| 2023 | 14 | 29 |
| 2024 | 18 | 33 |
| 2025 | 20 | 13 |
| 2026 | 8 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F15 Sep 2026US 12,734,229 B2Inventprise, LLC
- Vaccine21 Jul 2026US 12,685,769 B2Glaxosmithkline Biologicals SA
- Use of therapeutic compositions for the treatment of patients with tumors of epithelial origin7 Jul 2026US 12,673,107 B2Centro De Inmunologia Molecular
- Multivalent nanoparticle-based vaccines23 Jun 2026US 12,661,322 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof26 May 2026US 12,636,374 B2Pfizer Inc.
- Rhizavidin variants8 Oct 2026US 2026/0308208 A1Affinivax, Inc.
- Influenza neuraminidase tetramers13 Aug 2026US 2026/0234589 A1Icosavax, Inc.
- Tau and amyloid beta peptide immunogen compositions and related methods6 Aug 2026US 2026/0224676 A1Vaxxinity, Inc.
- Modified carrier proteins for o-linked glycosylation6 Aug 2026US 2026/0224696 A1Glaxosmithkline Biologicals SA
- Stabilized pfs48/45 proteins and uses thereof23 Jul 2026US 2026/0207725 A1The United States of America, as represented by the Secretary, Department of Health and Human
Most cited
By later US patents
- Submicron emulsions as vaccine adjuvants129US 5,961,970 APharmos Corporation · 1999
- Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response111US 5,830,702 AThe Trustees of the University of Pennsylvania · 1998
- Methods and vaccines comprising surface-active copolymers103US 5,554,372 AEmory University · 1996
- Vaccines102US 6,544,518 B1SmithKline Beecham Biologicals s.a. · 2003
- Pneumococcal polysaccharide conjugate vaccine98US 5,623,057 AMerck & Co., Inc. · 1997